Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Pazopanib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with sunitinib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Previous treated and treatment‐naïve (54%) metastatic renal cell carcinoma (clear cell type)
Pazopanib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with placebo (targeted agent versus placebo) (low certainty).
1 finding from 1 review
Intervention not reported
year overall survival in patients of good performance status (WHO performance status 0‐1) · adults with non small cell lung cancer who are not felt to be curable
1 finding from 1 review
Intervention not reported
year overall survival in patients of poor performance status (WHO performance status 2‐4) · adults with non small cell lung cancer who are not felt to be curable
The intervention showed no clear difference in year overall survival in patients of poor performance status (WHO… (moderate certainty).
1 finding from 1 review
Overall survival: higher‐dose WBRT vs control (3000 cGy/10 daily fractions)No. of participants: 846(4 RCTs) · patients with newly diagnosed multiple brain metastases
Altered WBRT fractionation schedules probably leads to higher overall survival: lower‐dose WBRT vs control WBRT (3000 cGy/10 daily… compared with WBRT control (moderate certainty).
2 findings from 1 review
HR 1.21 [1.04, 1.4]
Studies not reported
Moderate
HR 0.97 [0.83, 1.12]
Studies not reported
Moderate
Overall survival (absolute effect size estimates based on survival rate at 12 months) · participants with advanced hepatocellular carcinoma
It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes overall survival (absolute effect size estimates based on survival… compared with best supportive care alone (very low certainty).
1 finding from 1 review
Overall survival: WBRT 4000 cGy/20 fractions BID vs control WBRT (2000 cGy/4‐5 daily fractions)No. of participants: 203(2 RCTs) · patients with newly diagnosed multiple brain metastases
Altered WBRT fractionation schedules showed no clear difference in overall survival: WBRT 4000 cGy/20 fractions BID vs control WBRT… compared with WBRT control (moderate certainty).
1 finding from 1 review
HR 1.18 [0.89, 1.56]
Studies not reported
Moderate
Intervention not reported
Mortality sensitivity analysis (calculated instead of overall survival) ‐ without UK NCRI Rapid trial and MSKCC trial #90‐44due to high risk of other bias
The intervention probably leads to lower mortality sensitivity analysis (calculated instead of overall… (moderate certainty).
1 finding from 1 review